Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas

PAYDAŞ S., ERGİN M., ERDOĞAN Ş., SEYDAOĞLU G., Yavuz S., Disel U.

LEUKEMIA RESEARCH, vol.32, no.2, pp.243-250, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 2
  • Publication Date: 2008
  • Doi Number: 10.1016/j.leukres.2007.06.024
  • Journal Name: LEUKEMIA RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.243-250
  • Keywords: lymphoma, Survivin, thrombospondin-1, prognosis, agressivity, ACUTE MYELOID-LEUKEMIA, CHRONIC LYMPHOCYTIC-LEUKEMIA, N-TERMINAL DOMAIN, B-CELL-LYMPHOMAS, TUMOR-GROWTH, PROGNOSTIC-SIGNIFICANCE, IMPORTANT DETERMINANT, NUCLEAR SURVIVIN, DENDRITIC CELLS, APOPTOSIS
  • Çukurova University Affiliated: Yes

Abstract

Survivin (S) is a member of inhibitor of apoptosis family (IAP) and is expressed in the majority of malignant tumors but undetectable in normal differentiated adult tissues. S is an encouraging target for cancer therapy. TSP-1 is a multifunctional protein regulating cell growth, motility and apoptosis in both physiological and pathological conditions. The role of TSP-1 in cancer progression remains controversial. We aimed to determine the pathogenetic and prognostic role of TSP-1 and S in non-Hodgkin's lymphomas (NHL). S and TSP-1 expressions were looked for in 177 cases with NHL. S was found to be positive in 94 of the cases (53%). TSP-1 was found to be positive in 31 of the cases (17.5%). There was a strong association between S and TSP-1 and also aggressive histology with S and TSP-1. The overall survival (OS) times were longer in cases without S expression than cases with S expression (p = 0.0514). Although the OS was shorter in TSP-1 expressing cases as compared with TSP-1 (-) cases, difference was not significant (p = 0.2428).